Scientists Disable Alzheimer's 'Death Switch' in Mice
Heidelberg University neurobiologists identified a toxic protein complex driving Alzheimer's progression and used a novel compound to disrupt it in mice, preserving memory and reducing amyloid plaques.
A Toxic Partnership in the Brain
A team of neurobiologists led by Prof. Dr. Hilmar Bading at Heidelberg University has identified a molecular mechanism at the heart of Alzheimer's disease progression — and demonstrated that disabling it in mice can slow the disease, protect brain cells, and even reduce the hallmark amyloid plaques that have long been the primary target of Alzheimer's therapies.
The discovery, published in Molecular Psychiatry, centers on a destructive pairing of two proteins: the NMDA receptor, which normally supports neuron survival when operating at synapses, and the TRPM4 ion channel. When these two proteins interact outside synaptic regions, they form what the researchers call a "death complex" — a toxic unit that triggers brain cell destruction and cognitive decline.
How the Death Complex Works
NMDA receptors play a crucial role in learning and memory. Inside synapses, they help neurons communicate and survive. But when TRPM4 binds to NMDA receptors located outside synapses, it fundamentally alters their behavior, turning a life-sustaining signal into a death sentence for the cell.
The researchers found that this neurotoxic complex appears at far higher levels in Alzheimer's mouse models than in healthy animals. The complex drives a cascade of damage: synapse loss, mitochondrial dysfunction, and ultimately widespread neuronal death — all core features of Alzheimer's progression.
Breaking the Complex Apart
The team developed a compound called FP802, described as a "TwinF Interface Inhibitor." It works by binding to the precise contact surface — the "TwinF" interface — where TRPM4 and NMDA receptors connect. By occupying this docking point, FP802 prevents the two proteins from joining and effectively dissolves the toxic complex.
"Instead of targeting amyloid formation or removal, we are blocking a downstream cellular mechanism that can cause nerve cell death," Prof. Bading explained, highlighting how the approach differs fundamentally from existing Alzheimer's therapies like lecanemab and donanemab, which focus on clearing amyloid plaques from the brain.
Striking Results in Alzheimer's Mice
Working with a well-established Alzheimer's mouse model (5xFAD), the team — in collaboration with researchers at Shandong University in China — observed dramatic results when animals were treated with FP802:
- Disease progression was markedly slowed
- Synapse loss was limited or absent
- Mitochondrial damage was significantly reduced
- Learning and memory abilities remained largely intact
- Beta-amyloid plaque formation dropped significantly
The amyloid reduction was particularly notable. By targeting the downstream death mechanism rather than amyloid directly, the researchers appear to have disrupted a feedback loop in which neuronal damage itself promotes further amyloid accumulation.
A New Therapeutic Paradigm
Current Alzheimer's treatments have produced only modest benefits. Anti-amyloid antibodies, while representing genuine progress, slow cognitive decline by roughly 25–35% and carry risks of brain swelling and bleeding. The Heidelberg approach targets a different point in the disease cascade entirely, suggesting it could complement existing therapies or offer an alternative for patients who don't respond to amyloid-targeting drugs.
The researchers believe this inhibitor could represent a broadly applicable strategy for neurodegenerative diseases beyond Alzheimer's, including ALS, where excitotoxic cell death also plays a role.
However, Prof. Bading cautions that clinical use remains years away. "Comprehensive pharmacological development, toxicological experiments, and clinical studies are needed to realize a possible application in humans," he said. Dr. Jing Yan, a key collaborator now at FundaMental Pharma, is working to advance the compound toward clinical development.
For the estimated 55 million people worldwide living with dementia — a number projected to nearly triple by 2050 — even a distant prospect of a genuinely new therapeutic approach offers reason for cautious optimism.
